 The Food and Drug Administration on Wednesday approved Eli Lilly’s once-daily obesity pill targeting GLP-1, setting off a commercial fight with Novo Nordisk as the two metabolic drug giants seek to grab an increasing share of a market forecast to reach $100 billion a year by 2030. 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. |
